At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Market Closed 05-17 16:00:00 EDT
36.15
+0.27
+0.75%
盘后36.15
+0.000.00%
16:20 EDT
High36.75
Low35.29
Vol434.24K
Open35.88
D1 Closing35.88
Amplitude4.07%
Mkt Cap1.69B
Tradable Cap1.39B
Total Shares46.62M
T/O15.61M
T/O Rate1.13%
Tradable Shares38.42M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.